Brokers Offer Predictions for Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Omeros in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of ($1.73) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

Other equities research analysts also recently issued research reports about the company. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Thursday, January 16th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $9.15 on Wednesday. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The company has a 50 day moving average price of $9.45 and a 200 day moving average price of $6.07.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. MML Investors Services LLC boosted its stake in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares during the period. State Street Corp raised its holdings in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares in the last quarter. HighTower Advisors LLC boosted its position in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares during the last quarter. SG Americas Securities LLC grew its stake in Omeros by 21.2% in the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 4,257 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 6,435 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.